Pharmacophore modeling and in silico toxicity assessment of potential anticancer agents from African medicinal plants

Molecular modeling has been employed in the search for lead compounds of chemotherapy to fight cancer. In this study, pharmacophore models have been generated and validated for use in virtual screening protocols for eight known anticancer drug targets, including tyrosine kinase, protein kinase B β, cyclin-dependent kinase, protein farnesyltransferase, human protein kinase, glycogen synthase kinase, and indoleamine 2,3-dioxygenase 1. Pharmacophore models were validated through receiver operating characteristic and Güner–Henry scoring methods, indicating that several of the models generated could be useful for the identification of potential anticancer agents from natural product databases. The validated pharmacophore models were used as three-dimensional search queries for virtual screening of the newly developed AfroCancer database (~400 compounds from African medicinal plants), along with the Naturally Occurring Plant-based Anticancer Compound-Activity-Target dataset (comprising ~1,500 published naturally occurring plant-based compounds from around the world). Additionally, an in silico assessment of toxicity of the two datasets was carried out by the use of 88 toxicity end points predicted by the Lhasa’s expert knowledge-based system (Derek), showing that only an insignificant proportion of the promising anticancer agents would be likely showing high toxicity profiles. A diversity study of the two datasets, carried out using the analysis of principal components from the most important physicochemical properties often used to access drug-likeness of compound datasets, showed that the two datasets do not occupy the same chemical space.

[1]  R. M. Jayadeepa,et al.  Anti cancer activity on Graviola, an exciting medicinal plant extract vs various cancer cell lines and a detailed computational study on its potent anti-cancerous leads. , 2013, Current topics in medicinal chemistry.

[2]  Hsuan-Liang Liu,et al.  Structure-based pharmacophore modeling and virtual screening to identify novel inhibitors for anthrax lethal factor , 2014, Medicinal Chemistry Research.

[3]  J. Kuriyan,et al.  Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. , 2002, Cancer research.

[4]  Y. Zhan,et al.  Furanocoumarins-imperatorin inhibits myocardial hypertrophy both in vitro and in vivo. , 2010, Fitoterapia.

[5]  A. Kinghorn,et al.  The relevance of higher plants in lead compound discovery programs. , 2011, Journal of natural products.

[6]  D. Newman,et al.  Nature: a vital source of leads for anticancer drug development , 2009, Phytochemistry Reviews.

[7]  I. Muegge Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.

[8]  Ian Collins,et al.  Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. , 2007, Journal of medicinal chemistry.

[9]  C. Marchant,et al.  Computational toxicology: a tool for all industries , 2012 .

[10]  K. Lee,et al.  Anticancer drug design based on plant-derived natural products. , 1999, Journal of biomedical science.

[11]  C. Terreaux,et al.  Search for New Lead Compounds from Higher Plants , 2000, CHIMIA.

[12]  R. Ganju,et al.  Medicinal plants and cancer chemoprevention. , 2008, Current drug metabolism.

[13]  H. El‐Seedi,et al.  The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: discovery of an active cardiac glycoside from Urginea maritima. , 2013, Journal of ethnopharmacology.

[14]  W. Denny,et al.  The genetic toxicology of acridines. , 1991, Mutation research.

[15]  H. Hussain,et al.  Antimicrobial Coumarins from the Stem Bark of Afraegle paniculata , 2010, Natural product communications.

[16]  Andrew Marston,et al.  The Potential of African Plants as a Source of Drugs , 2000 .

[17]  P N Judson,et al.  Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.

[18]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[19]  J E Ridings,et al.  Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. , 1996, Toxicology.

[20]  Steven Fletcher,et al.  Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. , 2009, Chemistry & biology.

[21]  Connors Anticancer Drug Development: The Way Forward. , 1996, The oncologist.

[22]  Kazuhiro Uemoto,et al.  Pharmacophore-based design of sphingosine 1-phosphate-3 receptor antagonists that include a 3,4-dialkoxybenzophenone scaffold. , 2007, Journal of medicinal chemistry.

[23]  K. Bhoola,et al.  Natural products for cancer prevention: a global perspective. , 2003, Pharmacology & therapeutics.

[24]  Valerie J. Gillet,et al.  Automating Knowledge Discovery for Toxicity Prediction Using Jumping Emerging Pattern Mining , 2012, J. Chem. Inf. Model..

[25]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[26]  Hsuan-Liang Liu,et al.  The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies , 2011, Journal of Biomedical Science.

[27]  Pascal Amoa Onguéné,et al.  CamMedNP: Building the Cameroonian 3D structural natural products database for virtual screening , 2013, BMC Complementary and Alternative Medicine.

[28]  F. Dall'acqua,et al.  Investigation of the dark interaction between furocoumarins and DNA. , 1978, Chemico-biological interactions.

[29]  G. Klebe Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[30]  Sven Hellberg,et al.  Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. , 2012, Journal of medicinal chemistry.

[31]  Wolfgang Sippl,et al.  AfroDb: A Select Highly Potent and Diverse Natural Product Library from African Medicinal Plants , 2013, PloS one.

[32]  H. D. Showalter,et al.  Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. , 2000, Biochemical pharmacology.

[33]  D. Newman,et al.  Impact of natural products on developing new anti-cancer agents. , 2009, Chemical reviews.

[34]  Tetsuya Kohno,et al.  Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. , 2014, ACS medicinal chemistry letters.

[35]  Dharmaranjan Sriram,et al.  Enhanced ranking of PknB Inhibitors using data fusion methods , 2013, Journal of Cheminformatics.

[36]  Ying Sun,et al.  Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. , 2008, Journal of medicinal chemistry.

[37]  Y. Chin,et al.  Drug Discovery from Plants , 2008 .

[38]  Ping-Chiang Lyu,et al.  Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. , 2009, Journal of medicinal chemistry.

[39]  M. Gordaliza Natural products as leads to anticancer drugs , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[40]  D. Sanderson,et al.  Computer Prediction of Possible Toxic Action from Chemical Structure; The DEREK System , 1991, Human & experimental toxicology.

[41]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[42]  S. Capaccioli,et al.  Natural compounds for cancer treatment and prevention. , 2009, Pharmacological research.

[43]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[44]  A. Kinghorn,et al.  The continuing search for antitumor agents from higher plants. , 2010, Phytochemistry letters.

[45]  Jürg Zimmermann,et al.  Potent and Selective Inhibitors of the AbL-Kinase: Phenylaminopyrimidine (PAP) Derivatives. , 1997 .

[46]  D. Averbeck,et al.  Frameshift mutagenicity in Salmonella typhimurium of furocoumarins in the dark. , 1984, Mutation research.

[47]  D J Newman,et al.  Plants as a source of anti-cancer and anti-HIV agents , 2003 .

[48]  Peter M Fischer,et al.  Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. , 2010, Chemistry & biology.

[49]  Roberto Battistutta,et al.  Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. , 2011, Biochemistry.

[50]  Zigang Dong,et al.  Prediction of Molecular Targets of Cancer Preventing Flavonoid Compounds Using Computational Methods , 2012, PloS one.

[51]  K. Lee,et al.  Plant-derived anticancer agents and their analogs currently in clinical use or in clinical trials , 1997 .

[52]  Christopher T. Walsh,et al.  Lessons from natural molecules , 2004, Nature.

[53]  Gajendra P. S. Raghava,et al.  NPACT: Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database , 2012, Nucleic Acids Res..

[54]  D. Newman,et al.  Plant Natural Products in Anticancer Drug Discovery , 2010 .

[55]  M. Grever,et al.  Potential of plant-derived natural products in the treatment of leukemia and lymphoma. , 2010, Current drug targets.

[56]  J. Gibbs Mechanism-based target identification and drug discovery in cancer research. , 2000, Science.

[57]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[58]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[59]  W. Sippl,et al.  Binding of pyrazole-based inhibitors to Mycobacterium tuberculosis pantothenate synthetase: docking and MM-GB(PB)SA analysis. , 2014, Molecular bioSystems.

[60]  M. Wani,et al.  Plant antimutagenic agents, 1. General bioassay and isolation procedures. , 1988, Journal of natural products.

[61]  Ian Collins,et al.  Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. , 2008, Journal of medicinal chemistry.

[62]  S. Efange,et al.  Natural products: a continuing source of inspiration for the medicinal chemist , 2002 .

[63]  J N Weinstein,et al.  Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. , 2001, Journal of medicinal chemistry.

[64]  Philip N. Judson,et al.  How “drug-like” are naturally occurring anti-cancer compounds? , 2014, Journal of Molecular Modeling.

[65]  Zhaohui J. Cai,et al.  Pretreatment data is highly predictive of liver chemistry signals in clinical trials , 2012, Drug design, development and therapy.

[66]  D. Newman,et al.  Plants as a source of anti-cancer agents. , 2005, Journal of ethnopharmacology.

[67]  David J Newman,et al.  Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.

[68]  T. Efferth,et al.  Gems from traditional north-African medicine: medicinal and aromatic plants from Sudan , 2012, Natural Products and Bioprospecting.

[69]  Lilly M Saleena,et al.  Discovery of potent inhibitor for matrix metalloproteinase-9 by pharmacophore based modeling and dynamics simulation studies. , 2014, Journal of molecular graphics & modelling.

[70]  Tom Fawcett,et al.  An introduction to ROC analysis , 2006, Pattern Recognit. Lett..

[71]  Tsai-Wei Shen,et al.  A pharmacophore‐based evolutionary approach for screening selective estrogen receptor modulators , 2005, Proteins.

[72]  A. Gurib-Fakim,et al.  Medicinal plants: traditions of yesterday and drugs of tomorrow. , 2006, Molecular aspects of medicine.

[73]  N. Greene Computer Software for Risk Assessment , 1997, J. Chem. Inf. Comput. Sci..

[74]  Wolfgang Sippl,et al.  In silico drug metabolism and pharmacokinetic profiles of natural products from medicinal plants in the Congo basin , 2013, In Silico Pharmacology.

[75]  G. Aherne,et al.  Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)† , 2010, Journal of medicinal chemistry.

[76]  A. Negi,et al.  Plant-Based Anticancer Molecules: A Chemical and Biological Profile of Some Important Leads , 2012 .

[77]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[78]  Kazuo Kitaura,et al.  Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds. , 2012, Journal of medicinal chemistry.

[79]  Fang Wang,et al.  Optimized S-Trityl-l-cysteine-Based Inhibitors of Kinesin Spindle Protein with Potent in Vivo Antitumor Activity in Lung Cancer Xenograft Models , 2013, Journal of medicinal chemistry.

[80]  Wolfgang Sippl,et al.  Molecular Modeling of Potential Anticancer Agents from African Medicinal Plants , 2014, J. Chem. Inf. Model..

[81]  Marcy J. Balunas,et al.  Drug discovery from medicinal plants. , 2005, Life sciences.

[82]  W. Muster,et al.  Suppression of mutagenic activity of a series of 5HT2c receptor agonists by the incorporation of a gem-dimethyl group: SAR using the Ames test and a DNA unwinding assay. , 1998, Mutagenesis.

[83]  H. El‐Seedi,et al.  A Swedish collection of medicinal plants from Cameroon. , 2005, Journal of ethnopharmacology.

[84]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[85]  Heng Tao Shen,et al.  Principal Component Analysis , 2009, Encyclopedia of Biometrics.

[86]  V. Vyas,et al.  Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors. , 2013, Journal of molecular graphics & modelling.

[87]  Marc Schumacher,et al.  Traditional West African pharmacopeia, plants and derived compounds for cancer therapy. , 2012, Biochemical pharmacology.

[88]  Ki Young Lee,et al.  Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. , 2006, Journal of medicinal chemistry.

[89]  G. Kéri,et al.  Plant-derived protein tyrosine kinase inhibitors as anticancer agents. , 2004, Current medicinal chemistry. Anti-cancer agents.

[90]  M. Heinrich,et al.  Ethnobotany and ethnopharmacy--their role for anti-cancer drug development. , 2006, Current drug targets.

[91]  L. Pardo,et al.  Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line. , 2007, Journal of medicinal chemistry.

[92]  Adam Siddiqui-Jain,et al.  Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. , 2012, Bioorganic & medicinal chemistry letters.

[93]  Wolfgang Sippl,et al.  The potential of anti-malarial compounds derived from African medicinal plants, part III: an in silico evaluation of drug metabolism and pharmacokinetics profiling , 2014, Organic and medicinal chemistry letters.

[94]  Adam Siddiqui-Jain,et al.  7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. , 2011, Bioorganic & medicinal chemistry letters.

[95]  S. Kuduk,et al.  A common pharmacophore for cytotoxic natural products that stabilize microtubules. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[96]  P. Judson,et al.  Assessing the pharmacokinetic profile of the CamMedNP natural products database: an in silico approach , 2013, Organic and medicinal chemistry letters.

[97]  Arvind Saklani,et al.  Plant-derived compounds in clinical trials. , 2008, Drug discovery today.

[98]  Wolfgang Sippl,et al.  ConMedNP: a natural product library from Central African medicinal plants for drug discovery , 2014 .

[99]  Fidele Ntie-Kang,et al.  Virtualizing the p-ANAPL Library: A Step towards Drug Discovery from African Medicinal Plants , 2014, PloS one.

[100]  S. A. Fadeyi,et al.  In vitro anticancer screening of 24 locally used Nigerian medicinal plants , 2013, BMC Complementary and Alternative Medicine.

[101]  Jürg Zimmermann,et al.  Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .

[102]  D J Newman,et al.  The influence of natural products upon drug discovery. , 2000, Natural product reports.

[103]  P. Willett,et al.  PHARMACOPHORE PERCEPTION , DEVELOPMENT , AND USE IN DRUG DESIGN , 2011 .

[104]  H. Kubinyi Structure-based design of enzyme inhibitors and receptor ligands. , 1998, Current opinion in drug discovery & development.

[105]  Carol A Marchant,et al.  In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic , 2008, Toxicology mechanisms and methods.